Lineage Cell Therapeutics, Inc. (LCTX)
1.005
-0.02
(-2.43%)
USD |
NYAM |
Oct 30, 16:00
1.005
0.00 (0.00%)
After-Hours: 19:10
Lineage Cell Therapeutics Enterprise Value : 210.85M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 210.85M |
| October 28, 2026 | 213.38M |
| October 27, 2026 | 210.85M |
| October 26, 2026 | 202.48M |
| October 23, 2026 | 203.26M |
| October 22, 2026 | 199.47M |
| October 21, 2026 | 190.99M |
| October 20, 2026 | 196.33M |
| October 19, 2026 | 191.32M |
| October 16, 2026 | 197.77M |
| October 15, 2026 | 200.81M |
| October 14, 2026 | 182.39M |
| October 13, 2026 | 180.07M |
| October 12, 2026 | 191.65M |
| October 09, 2026 | 201.74M |
| October 08, 2026 | 210.85M |
| October 07, 2026 | 190.01M |
| October 06, 2026 | 187.55M |
| October 05, 2026 | 184.90M |
| October 02, 2026 | 185.63M |
| October 01, 2026 | 179.03M |
| September 30, 2026 | 192.06M |
| September 29, 2026 | 189.98M |
| September 28, 2026 | 195.93M |
| September 25, 2026 | 210.85M |
| Date | Value |
|---|---|
| September 24, 2026 | 190.06M |
| September 23, 2026 | 192.31M |
| September 22, 2026 | 213.38M |
| September 21, 2026 | 205.79M |
| September 18, 2026 | 210.85M |
| September 17, 2026 | 210.85M |
| September 16, 2026 | 220.96M |
| September 15, 2026 | 218.43M |
| September 14, 2026 | 220.96M |
| September 11, 2026 | 205.79M |
| September 10, 2026 | 208.32M |
| September 09, 2026 | 210.85M |
| September 08, 2026 | 226.02M |
| September 04, 2026 | 223.49M |
| September 03, 2026 | 228.55M |
| September 02, 2026 | 231.08M |
| September 01, 2026 | 223.49M |
| August 31, 2026 | 228.55M |
| August 28, 2026 | 231.08M |
| August 27, 2026 | 243.72M |
| August 26, 2026 | 233.61M |
| August 25, 2026 | 236.14M |
| August 24, 2026 | 226.02M |
| August 21, 2026 | 223.49M |
| August 20, 2026 | 223.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 566.80M |
| Amgen, Inc. | 292.39B |
| Anika Therapeutics, Inc. | 278.45M |
| BioCryst Pharmaceuticals, Inc. | 2.658B |
| Imunon, Inc. | 4.867M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.544M |
| Revenue (Quarterly) | 1.069M |
| Total Expenses (Quarterly) | -0.413M |
| EPS Diluted (Quarterly) | -0.0304 |
| Gross Profit Margin (Quarterly) | 82.51% |
| Earnings Yield | -18.34% |
| Normalized Earnings Yield | -13.77 |